14 March 2018

Contents

Editorial

• 14 March 2018: vol 19 no 5 – CROI 2018 part 1

Conference reports

• 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)

• Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques

• No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification

• Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment

• Twice-daily dolutegravir is effective and tolerable with rifampicin 

• Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin

• Efavirenz 400 mg can be given with anti-tuberculosis treatment 

• Bictegravir at CROI 2018: switching studies and drug resistance analyses

• PrEP at CROI 2018 (part 1): Access in Australia and the US

• PrEP at CROI 2018 (part 2): Animal studies for future drugs

• BHIVA best of CROI feedback workshops

Antiretrovirals

• FDA approves ibalizumab in the US to treat multidrug HIV resistance

PDFs

• 14 March 2018: vol 19 no 5